TactivinТактивин
A mixture of peptides extracted from thymus tissue, also called Taktivin, studied in immune-system research.
What the studies found
Comparison in people · 1996
Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
- Reported survival time
- 40 versus 24 monthsT-activin + surgery versus surgery aloneReported follow-upNot statistically significant
- Disease-free interval
- 17.5 versus 13 monthsSame comparison; described as similar
- Lymphoproliferative response
- Increase in 4 of 5 treated patients with progressionBiological response did not correspond to clinical benefit
In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.
Study notes · methods, sources and limitations
Participants or model 17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls
Design T-activin + surgery 8; surgery alone 9; early-stage melanoma; follow-up February 1991–August 1995.
- Participants
- 8 treated; 9 controls
Important limitations
- Very small adjunctive comparison; random allocation and blinding are not established by the abstract. Immune-marker changes did not correlate with clinical course and should not be presented as proven cancer benefit.
- The survival-time summary is not labeled as a median in the abstract. The small, non-randomized study does not establish a cancer-survival benefit.
Neoplasma. 43(4):245–252 · Indexed abstract
Comparison in people · 2011
Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison
Study of multiple preparations
- Clinical improvement
- 73.7% versus 57.1%Imunofan-based care versus the pooled thymic-peptide group. Denominators conflict in the paper.
- Fewer, shorter or no recurrences
- 36.8% versus 28.6%Composite reported in Table 2.
- Immunogram normalization
- 85.7% versus 84.3%Table 2. No formal between-group test given for these percentages.
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
More reported outcomes
- Temperature normalization
- 21% versus 14.3%
- Lower antiviral or antibacterial antibody titres
- 31.6% versus 14.3%
- CD3 lymphocytes
- 53.34 ± 1.55% to 65.8 ± 1.70%Within the Imunofan group.Reported p < 0.05
- CD4 lymphocytes
- 31.36 ± 1.29% to 36.95 ± 1.40%Within the Imunofan group.Reported p < 0.05
- Spontaneous IFN-γ
- 23.8 ± 2.47 to 42.13 ± 7.75 pg/mLWithin the Imunofan group.Reported p < 0.05
- Stimulated IFN-γ
- 1,669.7 ± 123.1 to 2,170.6 ± 89.8 pg/mLWithin the Imunofan group.Reported p < 0.05
Study notes · methods, sources and limitations
Participants or model Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
Design The methods list 35 patients per group but also give 29 women and 8 men in the Imunofan arm. Assignment followed order of presentation. Both groups received individualized care. The comparator pooled Thymalin, Thymogen and Tactivin. Lymphocyte markers and IFN-γ were assessed before and after treatment.
Important limitations
- The comparison group pooled Thymalin, Thymogen and Tactivin. The paper gives no drug-specific subgroup outcomes, so the rates cannot establish a difference versus any one preparation. The groups were assigned in order of presentation and differed in average age. Concurrent antimicrobial and immune-active treatment varied by clinical presentation. The Imunofan denominator conflicts within the methods, and Table 2 supplies percentages without event counts or a separate significance test. No systematic adverse-event results were reported.
- The Table 2 percentages are reproduced as published. The paper gives conflicting group sizes and no event counts, and the groups received different care. The IFN-γ and lymphocyte figures are within-group changes.
Public Health of the Far East. 2011;3(49):38–41. · Original journal article
Observational study · 1994
Clinico-immunologic effect of tactivin in chronic myeloid leukemia
- Infectious complications
- 1.77-fold reduction reportedRaw events and comparator denominator not supplied
Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.
Study notes · methods, sources and limitations
Participants or model 35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.
Design 35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.
- Assessed population
- 35 patients with advanced CML
Important limitations
- A historical adjunctive report, not evidence of leukemia control or survival benefit. The fold claim cannot be converted into absolute risk without denominators.
Gematologiia i transfuziologiia 1994 · Journal publication
About Tactivin
Names in this research collection
Taktivin
Identity / background source ↗
Research background
Thymus-derived polypeptide preparation studied as an immune adjunct and in animal learning models. Clinical findings include a reported infection reduction in leukemia and a neutral melanoma comparison.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
More study findings
Animal research · 2015
Thymus Polypeptide Preparation Tactivin Restores Learning and Memory in Thymectomied Rats
- Active-avoidance learning
- Restored with Tactivin; splenic polypeptides ineffective
Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.
Study notes · methods, sources and limitations
Participants or model Rats thymectomized at three weeks of age; active-avoidance learning assay.
Design Rats thymectomized at three weeks of age; active-avoidance learning assay.
- Reported regimen
- 0.5 mg/kg for 1 month after surgery
Important limitations
- An animal thymectomy model; no effect size, group counts or human cognitive outcomes are supplied in the indexed abstract.
Bulletin of experimental biology and medicine 2015 · Journal publication
Comparison in people · 2001
Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma
Study of multiple preparations
- Radiation complications and immune measures
- Improvement reported with both agents; Imunofan described as more effective; numerical rates absent
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Study notes · methods, sources and limitations
Participants or model Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Design Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Important limitations
- Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.
Eksperimental'naia i klinicheskaia farmakologiia 2001 · Journal publication
T-activin in an alternative-treatment patent
The 1991 psoriasis patent selected T-activin, Thymalin or Dalargin as alternatives alongside photochemotherapy. Its selected case results do not demonstrate an isolated peptide effect or a combined Thymalin–Dalargin regimen.
- Compound class
- Archival preparation lead
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Historical adjunctive clinical comparisons and observational reports
Study methods
Source-specific clinical abstracts and rat thymectomy experiment
Independent replication
Related reports are not automatically independent evidence
Source access
Primary-publication records linked; full-text versus abstract review shown per source
Safety evidence
Clinical safety, product equivalence and interactions not established by this collection
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Comparison in people · 2011
Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
Study notes and original source
Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison
· Original journal article
Y. V. Redkin, T. M. Lyuboshenko · Public Health of the Far East. 2011;3(49):38–41.
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
Results and tables
Reported findings and study design
The methods list 35 patients per group but also give 29 women and 8 men in the Imunofan arm. Assignment followed order of presentation. Both groups received individualized care. The comparator pooled Thymalin, Thymogen and Tactivin. Lymphocyte markers and IFN-γ were assessed before and after treatment.
Population or model Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
Dose, route and schedule
The paper reports 1 mL intramuscularly every three days for 10–15 injections. Its printed concentration differs from the product labeling, so the amount of active peptide per injection cannot be confirmed from this report.
Protocol source ↗ · Original methods, p. 40
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical improvement | 73.7% versus 57.1% | Imunofan-based care versus the pooled thymic-peptide group. Denominators conflict in the paper. |
| Fewer, shorter or no recurrences | 36.8% versus 28.6% | Composite reported in Table 2. |
| Immunogram normalization | 85.7% versus 84.3% | Table 2. No formal between-group test given for these percentages. |
| Temperature normalization | 21% versus 14.3% | |
| Lower antiviral or antibacterial antibody titres | 31.6% versus 14.3% | |
| CD3 lymphocytes | 53.34 ± 1.55% to 65.8 ± 1.70% | Within the Imunofan group. · Reported p < 0.05 |
| CD4 lymphocytes | 31.36 ± 1.29% to 36.95 ± 1.40% | Within the Imunofan group. · Reported p < 0.05 |
| Spontaneous IFN-γ | 23.8 ± 2.47 to 42.13 ± 7.75 pg/mL | Within the Imunofan group. · Reported p < 0.05 |
| Stimulated IFN-γ | 1,669.7 ± 123.1 to 2,170.6 ± 89.8 pg/mL | Within the Imunofan group. · Reported p < 0.05 |
The Table 2 percentages are reproduced as published. The paper gives conflicting group sizes and no event counts, and the groups received different care. The IFN-γ and lymphocyte figures are within-group changes.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
- Source reviewed
- Original issue PDF, pp. 38–41, including both tables and the methods.
Study limitations
- The comparison group pooled Thymalin, Thymogen and Tactivin. The paper gives no drug-specific subgroup outcomes, so the rates cannot establish a difference versus any one preparation.
- The groups were assigned in order of presentation and differed in average age. Concurrent antimicrobial and immune-active treatment varied by clinical presentation.
- The Imunofan denominator conflicts within the methods, and Table 2 supplies percentages without event counts or a separate significance test. No systematic adverse-event results were reported.
Reviewed 2026-11-10.
Experiment described in a patent · 1991
Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
Study notes and original source
Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
I. O. Malova, R. G. Skvortsova, N. P. Kuznetsova · SU1674849A1 · patent family 21434935
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
Results and tables
Reported patent results
Reported findings
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
Population or model Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Alternative-treatment examples | Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14% | One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects |
| Dalargin case: immune measures | T-suppressor index 9%→25%; T-helper index 71%→55% | Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements |
| Thymalin case: immune measures | T-suppressor index 33%→30%; T-helper index 35%→57% | Example 3; B cells 32%→13% |
| T-activin case: immune measures | T-suppressor index 40%→34%; T-helper index 31.4%→52% | Example 1; B cells 28.6%→14% |
| Clinical course in selected cases | Discharge reported on day 19 with Dalargin and day 21 with Thymalin or T-activin | Individual clinical descriptions; no matched control or causal days-saved estimate |
| Russian-text peptide schedules | Dalargin 1 mg intramuscularly twice daily for 5 days; Thymalin 5 mg intramuscularly once daily for 4 days; or T-activin 50 µg subcutaneously daily for 5 days | Alternative historical treatments with photochemotherapy, not a combined or current prescribing regimen |
| Translation and extraction gaps | English abstract mistranslates T-activin as 50 mg; one Thymalin case mistranslates frequency as four times daily | Russian text and course totals specify 50 µg and once daily, respectively. Patent PDF and aggregate comparison table not recovered. |
Three selected patent cases: before → after
| Historical immune measure | Dalargin, example 2 | Thymalin, example 3 | T-activin, example 1 |
|---|---|---|---|
| B-lymphocytes (%) | 10→20 | 32→13 | 28.6→14 |
| T-suppressor index (%) | 9→25 | 33→30 | 40→34 |
| T-helper index (%) | 71→55 | 35→57 | 31.4→52 |
Case descriptions, not study-arm means; n=1 selected patient per preparation. Photochemotherapy was concurrent. Historical subset labels do not establish modern regulatory-T-cell phenotypes.
This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.
- This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-08.
Animal research · 2015
Thymus Polypeptide Preparation Tactivin Restores Learning and Memory in Thymectomied Rats
Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.
Study notes and original source
Thymus Polypeptide Preparation Tactivin Restores Learning and Memory in Thymectomied Rats
Thymus-derived polypeptide preparation · Journal publication
Novoseletskaya AV, Kiseleva NM, Zimina IV, Bystrova OV, Belova OV, Inozemtsev AN, Arion VY, Sergienko VI · Bulletin of experimental biology and medicine 2015
Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.
Results and tables
Reported findings and study design
Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.
Rats thymectomized at three weeks of age; active-avoidance learning assay.
Population or model Rats thymectomized at three weeks of age; active-avoidance learning assay.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Active-avoidance learning | Restored with Tactivin; splenic polypeptides ineffective | |
| Reported regimen | 0.5 mg/kg for 1 month after surgery |
An animal thymectomy model; no effect size, group counts or human cognitive outcomes are supplied in the indexed abstract.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Rats thymectomized at three weeks of age; active-avoidance learning assay.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- An animal thymectomy model; no effect size, group counts or human cognitive outcomes are supplied in the indexed abstract.
Reviewed 2026-11-01.
Observational study · 1994
Clinico-immunologic effect of tactivin in chronic myeloid leukemia
Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.
Study notes and original source
Clinico-immunologic effect of tactivin in chronic myeloid leukemia
Thymus-derived polypeptide preparation · Journal publication
Abdulkadyrov KM, Guseva SA · Gematologiia i transfuziologiia 1994
Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.
Results and tables
Reported findings and study design
Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.
35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Infectious complications | 1.77-fold reduction reported | Raw events and comparator denominator not supplied |
| Assessed population | 35 patients with advanced CML |
A historical adjunctive report, not evidence of leukemia control or survival benefit. The fold claim cannot be converted into absolute risk without denominators.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- A historical adjunctive report, not evidence of leukemia control or survival benefit. The fold claim cannot be converted into absolute risk without denominators.
Reviewed 2026-11-01.
Comparison in people · 2001
Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Study notes and original source
Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma
Tactivin tissue extract and synthetic Imunofan as separate comparisons · Journal publication
Venediktova MG · Eksperimental'naia i klinicheskaia farmakologiia 2001
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Results and tables
Reported findings and study design
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Population or model Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Radiation complications and immune measures | Improvement reported with both agents; Imunofan described as more effective; numerical rates absent |
Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- Group sizes, allocation details, complication counts and cancer-survival endpoints are unavailable. A 2004 Tver abstract by Gladkova and colleagues includes Venediktova as a coauthor. Participant overlap is unresolved.
Reviewed 2026-11-01.
Comparison in people · 1996
Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.
Reported survival time · 40 versus 24 months · T-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant
Study notes and original source
Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
T-activin thymus preparation
Format: Journal article · Reviewed: Indexed abstract reviewed
N. Stanojević-Bakić, D. Milosević, L. Vucković-Dekić, M. Sasić, L. Marković · Neoplasma. 43(4):245–252
In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.
Results and tables
Reported findings and study design
In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.
T-activin + surgery 8; surgery alone 9; early-stage melanoma; follow-up February 1991–August 1995.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported survival time | 40 versus 24 months | T-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant |
| Disease-free interval | 17.5 versus 13 months | Same comparison; described as similar |
| Lymphoproliferative response | Increase in 4 of 5 treated patients with progression | Biological response did not correspond to clinical benefit |
| Participants | 8 treated; 9 controls |
The survival-time summary is not labeled as a median in the abstract. The small, non-randomized study does not establish a cancer-survival benefit.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls
- Source reviewed
- Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
- Very small adjunctive comparison; random allocation and blinding are not established by the abstract.
- Immune-marker changes did not correlate with clinical course and should not be presented as proven cancer benefit.
Reviewed 2026-11-01.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗